visualizations
Tejani, Mohamedtaki, MD
Overview
overview
- Mohamedtaki A. Tejani, MD, received his Bachelor of Arts degree, Magna Cum Laude, from Amherst College. He later earned his medical degree from Dartmouth Medical School. Dr. Tejani went on to complete his residency at Yale-New Haven Hospital in New Haven, CT, achieving the rank of Chief Resident. Following this, he completed his fellowship training in hematology/oncology at Fox Chase Cancer Center/Temple University in Philadelphia. An award-winning physician, Dr. Tejani has authored numerous oncology-related publications. His research experience and areas of interest include gastrointestinal cancers, biomarkers and therapeutics, patient-provider communication and the culture of medicine. Dr. Tejani firmly believes that patient care is a privilege. Listening and responding to a patient’s unique story is critical in helping that family on their cancer journey. Originally from Tanzania (East Africa), he is fluent in Swahili, Hindi, Urdu and Gujarati.
Affiliation
Member of
-
Clinical Program
-
Research Department
Publications
Most Recent Publications
-
2024A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer. FUTURE ONCOLOGY.Full Text via DOI: 10.1080/14796694.2024.2368952 PMID: 39114870
-
2024Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. ONCOLOGIST.Full Text via DOI: 10.1093/oncolo/oyae155 PMID: 39022993
-
2024Zanidatamab (zani) in previously treated HER2+biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study. JOURNAL OF CLINICAL ONCOLOGY. 450-450.Full Text via DOI: 10.1200/JCO.2024.42.3_suppl.450
-
2023Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States. WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. 15:1796-1806.Full Text via DOI: 10.4251/wjgo.v15.i10.1796 PMID: 37969411
-
2023Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study. ANNALS OF ONCOLOGY. S219-S219.Full Text via DOI: 10.1016/j.annonc.2023.09.1394
-
2023Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. LANCET ONCOLOGY. 24:772-782.Full Text via DOI: 10.1016/S1470-2045(23)00242-5 PMID: 37276871
-
2022Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. ONCOLOGIST.Full Text via DOI: 10.1093/oncolo/oyac249 PMID: 36562592
-
2022Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma. ANNALS OF ONCOLOGY. S1469-S1469.Full Text via DOI: 10.1016/j.annonc.2022.10.126
-
2022A phase II (ph2), randomized study of magrolimab with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable metastatic colorectal cancer (mCRC). ANNALS OF ONCOLOGY. S735-S735.Full Text via DOI: 10.1016/j.annonc.2022.07.577
-
2021Comparing Needles and Methods of Endoscopic Ultrasound-Guided Fine-Needle Biopsy to Optimize Specimen Quality and Diagnostic Accuracy for Patients With Pancreatic Masses in a Randomized Trial. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 19:825-+.Full Text via DOI: 10.1016/j.cgh.2020.06.042 PMID: 32652307
-
2021Associations of Uncertainty With Psychological Health and Quality of Life in Older Adults With Advanced Cancer. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 61:369-+.Full Text via DOI: 10.1016/j.jpainsymman.2020.08.012 PMID: 32822750
-
2021A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma.. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2021.39.3_suppl.TPS453
-
2021DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial. ANNALS OF ONCOLOGY. S1048-S1049.Full Text via DOI: 10.1016/j.annonc.2021.08.1493
-
2020Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience. CLINICAL COLORECTAL CANCER. 19:E124-E128.Full Text via DOI: 10.1016/j.clcc.2020.03.008 PMID: 32409226
-
2019Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma. ANNALS OF THORACIC SURGERY. 108:343-349.Full Text via DOI: 10.1016/j.athoracsur.2019.04.004 PMID: 31059681
-
2019Opportunities for cannabis in supportive care in cancer. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.Full Text via DOI: 10.1177/1758835919866362 PMID: 31413731
-
2019Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. FUTURE ONCOLOGY. 15:2073-2082.Full Text via DOI: 10.2217/fon-2019-0141 PMID: 31094225
-
2019Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. SUPPORTIVE CARE IN CANCER. 27:1765-1774.Full Text via DOI: 10.1007/s00520-018-4424-6 PMID: 30151681
-
2019Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?. JOURNAL OF GASTROINTESTINAL ONCOLOGY. 10:357-361.Full Text via DOI: 10.21037/jgo.2018.09.05 PMID: 31032106
-
2019The Influence of Patient Race and Activation on Pain Management in Advanced Lung Cancer: a Randomized Field Experiment. JOURNAL OF GENERAL INTERNAL MEDICINE. 34:435-442.Full Text via DOI: 10.1007/s11606-018-4785-z PMID: 30632104
-
2019A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. ONCOLOGIST. 24:161-+.Full Text via DOI: 10.1634/theoncologist.2018-0654 PMID: 30352941
-
2018Patterns of interactions among patients with advanced pancreatic cancer, their caregivers, and healthcare providers during symptom discussions. SUPPORTIVE CARE IN CANCER. 26:3497-3506.Full Text via DOI: 10.1007/s00520-018-4202-5 PMID: 29696423
-
2018Symptom experiences in patients with advanced pancreatic cancer as reported during healthcare encounters. EUROPEAN JOURNAL OF CANCER CARE. 27.Full Text via DOI: 10.1111/ecc.12838 PMID: 29600524
-
2017Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOLOGY. 18:1467-1482.Full Text via DOI: 10.1016/S1470-2045(17)30566-1 PMID: 28958504
-
2017The social and behavioral influences (SBI) study: study design and rationale for studying the effects of race and activation on cancer pain management. BMC CANCER. 17.Full Text via DOI: 10.1186/s12885-017-3564-2 PMID: 28841847
-
2017Chemotherapy-induced peripheral neuropathy clinical trials Review and recommendations. NEUROLOGY. 859-869.Full Text via DOI: 10.1212/WNL.0000000000004272 PMID: 28747442
-
2017Variation in Delayed Time to Adjuvant Chemotherapy and Disease-Specific Survival in Stage III Colon Cancer Patients. ANNALS OF SURGICAL ONCOLOGY. 24:1610-1617.Full Text via DOI: 10.1245/s10434-016-5622-4 PMID: 27738848
-
2017Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy SWOG S1115 Study Randomized Clinical Trial. JAMA ONCOLOGY. 3:516-522.Full Text via DOI: 10.1001/jamaoncol.2016.5383 PMID: 27978579
-
2017The impact of age on complications, survival, and cause of death following colon cancer surgery. BRITISH JOURNAL OF CANCER. 116:389-397.Full Text via DOI: 10.1038/bjc.2016.421 PMID: 28056465
-
2017Poor Compliance With Adjuvant Chemotherapy Use Associated With Poorer Survival in Patients With Rectal Cancer: An NCDB Analysis. CANCER. 123:52-61.Full Text via DOI: 10.1002/cncr.30261 PMID: 27560162
-
2016Variation in Hospital-Specific Rates of Suboptimal Lymphadenectomy and Survival in Colon Cancer: Evidence from the National Cancer Data Base. ANNALS OF SURGICAL ONCOLOGY. 23:S674-S683.Full Text via DOI: 10.1245/s10434-016-5551-2 PMID: 27613558
-
2016A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015). ANNALS OF ONCOLOGY. 1180-1180.Full Text via DOI: 10.1093/annonc/mdw095 PMID: 26945010
-
2016Evaluating the Prognostic Role of Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer Patients: Results from the National Cancer Database. ANNALS OF SURGICAL ONCOLOGY. 23:1554-1561.Full Text via DOI: 10.1245/s10434-015-5014-1 PMID: 26759308
-
2016Relationships between personal attitudes about death and communication with terminally ill patients: How oncology clinicians grapple with mortality. PATIENT EDUCATION AND COUNSELING. 99:356-363.Full Text via DOI: 10.1016/j.pec.2015.10.010 PMID: 26519993
-
2016Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.. Advances in radiation oncology. 35-42.Full Text via DOI: 10.1016/j.adro.2015.12.003 PMID: 28799575
-
2016Watch and Wait?-Elevated Pretreatment CEA Is Associated with Decreased Pathological Complete Response in Rectal Cancer. JOURNAL OF GASTROINTESTINAL SURGERY. 20:43-52.Full Text via DOI: 10.1007/s11605-015-2987-9 PMID: 26546119
-
2015A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer (vol 26, pg 1923, 2015). ANNALS OF ONCOLOGY. 2505-2505.Full Text via DOI: 10.1093/annonc/mdv477 PMID: 26489442
-
2015A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer(aEuro). ANNALS OF ONCOLOGY. 26:1923-1929.Full Text via DOI: 10.1093/annonc/mdv264 PMID: 26091808
-
2015Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused. SURGERY. 158:692-699.Full Text via DOI: 10.1016/j.surg.2015.03.057 PMID: 26032822
-
2015Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS. 221:430-440.Full Text via DOI: 10.1016/j.jamcollsurg.2015.04.010 PMID: 26206642
-
2014Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. 12:1123-1130.PMID: 25099444
-
2014Pancreatic Neuroendocrine Tumors: Does Chemotherapy Work?. JOURNAL OF THE PANCREAS. 15:132-134.PMID: 24618436
-
2014Anticipatory nausea and vomiting due to chemotherapy.. European journal of pharmacology. 172-9.Full Text via DOI: 10.1016/j.ejphar.2013.09.071 PMID: 24157982
-
2013Head and neck sarcomas: a comprehensive cancer center experience.. CANCERS. 890-900.Full Text via DOI: 10.3390/cancers5030890 PMID: 24202325
-
2013Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. SUPPORTIVE CARE IN CANCER. 21:2059-2066.Full Text via DOI: 10.1007/s00520-013-1766-y PMID: 23446880
-
2013Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. EXPERT OPINION ON PHARMACOTHERAPY. 757-766.Full Text via DOI: 10.1517/14656566.2013.776541 PMID: 23496347
-
2012Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. CURRENT TREATMENT OPTIONS IN ONCOLOGY. 13:390-402.Full Text via DOI: 10.1007/s11864-012-0193-5 PMID: 22592595
-
2010The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. BIOLOGICS-TARGETS & THERAPY. 173-185.PMID: 20714355
-
2007Safety of capecitabine use in patients with liver dysfunction.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 730-736.PMID: 17982413
Background
Full Name
- Mohamedtaki Tejani, MD
Education
- Dartmouth Medical School, Hanover, NH
- University of Rochester School of Medicine, Rochester, NY
Residency
- Yale-New Haven Medical Center, New Haven, CT
Fellowship
- Fox Chase Cancer Center/Temple University, Philadelphia, PA
Contact
primary email
- Research.Institute@AdventHealth.com